Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07825701) titled 'Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations' on Sept. 11.
Study Type: Expanded Access
Primary Sponsor: GlaxoSmithKline
Condition:
Gastrointestinal Neoplasms
Intervention:
Drug: Velzatinib (GSK6042981)
Recruitment Status: Not recruiting
Date of First Enrollment: September 15, 2026
To know more, visit https://clinicaltrials.gov/study/NCT07825701
Disclaimer: Curated by HT Syndication....